Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 double-blind, randomized study of COYA 301 in patients with mild to moderate AD

Next Previous
Trial Profile

A phase 2 double-blind, randomized study of COYA 301 in patients with mild to moderate AD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COYA-301 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Coya Therapeutics

Most Recent Events

  • 13 May 2025 According to a Coya Therapeutics media release, company will report additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD) 2025.
  • 01 Apr 2025 According to a Coya Therapeutics media release, company announced that the principal investigator of this study Alireza Faridar, M.D will be presenting data from his study at the ADPD 2025 conference in Vienna.
  • 18 Mar 2025 According to a Coya Therapeutics media release, Additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer disease is expected in second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top